Russian COVID-19 Vaccine Shows 91.6% Efficacy

A peer-reviewed study in the highly regarded journal The Lancet found that Sputnik V, a new COVID-19 vaccine developed in Russia, was 91.6% effective in preventing infection with the novel coronavirus. The study included 22,000 subjects and no significant side effects were reported. Sputnik V requires two doses but does not need sub-zero storage like the Pfizer and Moderna vaccines. Developed by the Gamaleya Research Institute—part of the Russian government’s health department—the vaccine has been in use in Russia since August 2020, even without the support of large-scale clinical trial results. Thus far, more than 50 countries have placed orders for the Sputnik V vaccine and it is currently being administered in Algeria, Hungary, Iran, and Venezuela. Click here to read more.